Form 4: Myriad Genetics CEO Samraat Raha Acquires Shares Through Employee Stock Purchase Plan

Myriad Genetics, Inc. President and CEO, Samraat S. Raha, acquired 1,498 shares of common stock on May 31, 2025, through the company's Employee Stock Purchase Plan.

Summary

• Samraat S. Raha, President and CEO, and a Director of Myriad Genetics, Inc. (MYGN), acquired 1,498 shares of the company's common stock.
• The transaction occurred on May 31, 2025, at a price of $3.562 per share.
• These shares were acquired under the Myriad Genetics, Inc. Amended and Restated 2012 Employee Stock Purchase Plan (ESPP).
• The acquisition is exempt under SEC Rules 16b-3(d) and 16b-3(c).
• Following this transaction, Samraat S. Raha beneficially owns a total of 482,738 shares of Myriad Genetics common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the transaction size is relatively small, it represents an insider acquisition, which generally signals confidence. Being an ESPP purchase, it's a routine and expected event, not indicative of a major strategic shift, but still a positive reinforcement of management's alignment with shareholder interests.

Positives

• The acquisition of shares by a key executive like the President and CEO, Samraat S. Raha, can signal confidence in the company's future prospects.
• Participation in the Employee Stock Purchase Plan (ESPP) demonstrates alignment of management's interests with those of shareholders.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook; it solely reports an insider's stock transaction.

Management Comments

• The acquisition of shares by President and CEO Samraat S. Raha through the Employee Stock Purchase Plan implicitly demonstrates management's continued investment in and commitment to the company.

Industry Context

In the biotechnology and genetic testing industry, insider transactions, particularly acquisitions, can be viewed as a positive indicator of management's belief in the company's long-term strategy and market position. This specific transaction, being an ESPP acquisition, is a routine and common form of insider ownership increase.

Related Party Transactions

• The acquisition of shares by Samraat S. Raha under the Myriad Genetics, Inc. Amended and Restated 2012 Employee Stock Purchase Plan constitutes a related party transaction, as it involves an executive purchasing company stock through an employee benefit program.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, indicating management's belief in the company's value and future performance.
• Employees participating in the ESPP benefit from the opportunity to acquire company stock at a potentially favorable price, aligning their financial interests with the company's success.

Key Dates

Recommendation

Keywords

Myriad Genetics, MYGN, Samraat S. Raha, Form 4, Insider Trading, Stock Acquisition, Employee Stock Purchase Plan, ESPP, Biotechnology, Genetic Testing